

---

## **THE HIDDEN CULPRIT OF MALE INFERTILITY: SERTOLI CELL-ONLY SYNDROME (DEL CASTILLO SYNDROME OR GERM CELL APLASIA): SCHOLARLY REVIEW ARTICLE**

**Dr. Yasin Mansuri\***

Department of Biomedical technology (BMTC), Gujarat University, Ahmedabad.

---

### **ABSTRACT**

The Sertoli Cell-Only Syndrome (SCOS), also documented as Del Castillo syndrome or germ cell aplasia, is a exceptional histopathological situation of the testes categorized by the complete lack of germ cells within the seminiferous tubules, leaving only Sertoli cells. It also represents an significant cause of non-obstructive azoospermia (NOA) and male infertility. The cause of SCOS is multifactorial, linking genetic disease, environmental influences, and cryptogenic mechanisms. Male sex glands (Testes) from male with hypogonadotropic hypogonadism showed only immature Sertoli cells; cryptorchid testes showed dysgenetic cells and occasional typical cells; and after heal with oestrogens or chemotherapy the testes showed involuting cells and normal cells. This review paper highlights the existing perceptive of SCOS, consist of its pathogenesis, analytical approach, and therapeutic strategy, while emphasizing modern advances in reproductive medication and forthcoming upcoming strategy.

---

**Keywords:** Sertoli Cell-Only Syndrome, Azoospermia, Leydig cells, seminiferous tubules

### **INTRODUCTION**

Infertility affects roughly 15% of couples global, and male factors account for nearly half of these cases. The etiologies of male infertility, non-obstructive azoospermia (NOA) is particularly challenging. SCOs are a classic form of NOA, first described in 1947 by Del Castillo(1). Patients with SCOS typically present with infertility despite common secondary sexual character. Histologically, seminiferous tubules include only Sertoli cells, with a complete lack of spermatogonia and other germ cell lineages. Several patients can still reproduce with assisted reproductive technology (ART). This action describes the diagnosis and treatment of germ cell aplasia and highlights the interprofessional team's responsibility in supervision these patients.

Men often have Sertoli cell-only syndrome stuck between the ages of 20 and 40 when they are checked for infertility and found to produce no sperm (Azoospermia). Other signs and symptoms are infrequent, yet in a few cases, an underlying cause of SCO syndrome, such as Klinefelter syndrome, may produce other symptoms.

### **ETIOLOGY AND PATHOPHYSIOLOGY OF SCOs**

The pathogenesis of SCOS is heterogeneous:

**Genetic Factors:** Deletions in the Y chromosome, particularly AZF (azoospermia factor) regions, are strongly associated with SCOS (2,3). Mutations in genes regulating germ cell proliferation and meiosis may also contribute.

**Environmental and Acquired Factors:** Testicular trauma, cryptorchidism, chemotherapy, radiotherapy, and toxin exposure may result in germ cell depletion (4).

**Idiopathic Cases:** In many patients, the cause remains unidentified despite extensive evaluation (5).

The nonexistence of germ cells impairs spermatogenesis, although Sertoli cells and Leydig cells typically remain functional, preserving androgen production.

## CAUSES

Genetic defects (e.g., microdeletions on the Y chromosome, especially AZF region).

Chromosomal abnormalities (e.g., Klinefelter syndrome in some cases).

### Acquired causes:

Testicular trauma

Radiation or chemotherapy

Orchitis (inflammation of testes, e.g., mumps orchitis)

## CLINICAL FEATURES

**Infertility:** The most common presentation is inability to conceive.

**Semen Analysis:** Azoospermia is the hallmark finding.

**Hormonal Profile:** Serum FSH levels are usually elevated due to lack of inhibin B feedback, while LH and testosterone may remain normal (6).

**Physical Examination:** Testicular volume may be reduced, though some patients present with normal testicular size and virilization.

## DIAGNOSIS

Definitive diagnosis of SCOS requires testicular biopsy, demonstrating seminiferous tubules lined exclusively with Sertoli cells (7). Additional diagnostic modalities include:

**Semen Analysis:** Confirmation of azoospermia on at least two samples.

**Hormonal Studies:** Elevated FSH with normal or slightly reduced testosterone (6).

Genetic Testing: Karyotyping and Y-chromosome microdeletion studies are essential to rule out underlying chromosomal defects (3,8).

Ultrasound: Testicular size and echotexture may support diagnosis.

## **MANAGEMENT**

There is no definitive cure for SCOS, but management strategies focus on fertility options and supportive care:

Assisted Reproductive Techniques (ART): Testicular sperm extraction (TESE) combined with intracytoplasmic sperm injection (ICSI) may retrieve sperm in cases of focal spermatogenesis (9).

Donor Sperm Insemination: An alternative for patients with complete germ cell aplasia.

Counseling and Psychological Support: Essential for coping with infertility diagnosis (10).

Experimental Therapies: Stem cell therapy, germ cell transplantation, and gene editing are under investigation but not yet clinically available (11).

## **FUTURE PERSPECTIVES**

Advances in molecular genetics and regenerative medicine may revolutionize SCOS management. Identification of novel genetic markers could improve early diagnosis and personalized treatment. Moreover, stem-cell based strategies may offer potential avenues for restoring spermatogenesis in the future.

## **CONCLUSION**

Sertoli Cell-Only Syndrome (SCOs) is a noteworthy reason of male infertility characterized by germ cell aplasia within the seminiferous tubules. Although current treatments are inadequate, advances in assisted reproductive technology provide hope for affected patients. Sustained investigation into genetic, molecular, and regenerative mechanisms is vital to developing efficient therapy. However, the condition remains largely irreversible, with limited therapeutic options. Assisted reproductive techniques, including testicular sperm extraction and intracytoplasmic sperm injection in rare focal spermatogenesis, provide some hope. Eventually, Del Castillo Syndrome or SCOs exemplifies the intricate interplay between genetics, endocrinology, and reproductive medicine, highlighting the need for multidisciplinary approaches to manage and potentially overcome this challenge.

## **REFERENCES**

1. Del Castillo EB, Trabucco A, De La Balze FA. Syndrome produced by absence of germinal epithelium without impairment of Sertoli or Leydig cells. *J Clin Endocrinol Metab.* 1947;7(7):493-502.
2. Vogt PH, Edelmann A, Kirsch S, Henegariu O, Hirschmann P, Kiesewetter F, et al. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. *Hum Mol Genet.* 1996;5(7):933-43.
3. Krausz C, Hoefsloot L, Simoni M, Tüttelmann F; European Academy of Andrology; European Molecular Genetics Quality Network. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: State-of-the-art 2013. *Andrology.* 2014;2(1):5-19.

4. Hentrich M, Ohl J, Oosterhuis JW, Schaller S, Bokemeyer C. Cancer therapy and male fertility: Risks and management. *Onkologie*. 2001;24(4):326-32.
5. Sadri-Ardekani H, Atala A. Regenerative medicine for male infertility. *Stem Cell Res Ther*. 2014;5(6):122.
6. Tüttelmann F, Rajpert-De Meyts E, Nieschlag E, Simoni M. Gene polymorphisms and male infertility – a meta-analysis and literature review. *Reprod Biomed Online*. 2007;15(6):643-58.
7. Holstein AF, Schulze W, Davidoff M. Understanding spermatogenesis is a prerequisite for treatment. *Reprod Biol Endocrinol*. 2003;1:107.
8. Foresta C, Moro E, Ferlin A. Y chromosome microdeletions and alterations of spermatogenesis. *Endocr Rev*. 2001;22(2):226-39.
9. Schlegel PN. Testicular sperm extraction: Microdissection improves sperm yield with minimal tissue excision. *Hum Reprod*. 1999;14(1):131-5.
10. Wischmann T, Thorn P. (Un)fulfilled desire for children in men: Impact on health and quality of life. *J Psychosom Res*. 2013;74(6):543-8.
11. Easley CA, Simerly CR, Schatten G. Stem cell therapeutic possibilities for male infertility. *Expert Opin Biol Ther*. 2013;13(9):1229-41.